Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANG Lifesciences India's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was ₹10.7 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-50.8 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
ANG Lifesciences India's annualizedROC % for the quarter that ended in Mar. 2026 was 2.31%.
ANG Lifesciences India's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.68%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
ANG Lifesciences India's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.38%.
ANG Lifesciences India (BOM:540694) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
ANG Lifesciences India's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-50.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANG Lifesciences India (BOM:540694) has a EBIT of ₹-50.8 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ANG Lifesciences India.
Is ANG Lifesciences India's EBIT too high?
ANG Lifesciences India's current EBIT is ₹-50.8 Mil. Overall, ANG Lifesciences India has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's EBIT compare to ZTS and UTHR?
ANG Lifesciences India's EBIT of ₹-50.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ANG Lifesciences India. ANG Lifesciences India's current EBIT is ₹-50.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹30.61, compared to a current price of ₹34.01 — trading 11.1% above its estimated fair value. The current EBIT is ₹-50.8 Mil. ANG Lifesciences India's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current EBIT is ₹-50.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued.
The current stock price of ₹34.01 is trading 11.1% above its estimated GF Value™ of ₹30.61.
GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.
Key valuation signals for BOM:540694:
EBIT: ₹-50.8 Mil
GF Value™: ₹30.61 vs. price of ₹34.01 (11.1% above fair value)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score
Get the complete analysis for BOM:540694
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
